Elvucitabine

DRUG5 trials

Sponsors

Alexion Pharmaceuticals, Inc., Thomas Jefferson University

Conditions

HIV InfectionsHuman Immunodeficiency Virus (HIV)-1 Infection

Phase 1

Study of Once Daily Elvucitabine Versus Lamivudine in Participants With a Documented M184V Mutation

CompletedNCT00312039

Alexion Pharmaceuticals, Inc.HIV Infections

Start: 2006-03-31End: 2007-10-31Target: 20Updated: 2023-08-25

Phase 2

Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants

CompletedNCT00350272

Alexion Pharmaceuticals, Inc.HIV Infections

Start: 2006-05-31End: 2009-04-30Updated: 2023-08-30

Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014A

CompletedNCT00380159

Alexion Pharmaceuticals, Inc.Human Immunodeficiency Virus (HIV)-1 Infection

Start: 2006-09-30End: 2009-01-31Updated: 2023-08-14

Safety Study of Elvucitabine in HIV-1 Subjects

CompletedNCT00405249

Thomas Jefferson UniversityHIV Infections

Start: 2006-09-30End: 2006-11-30Target: 5Updated: 2009-02-04

An Open-Label Treatment Protocol to Provide Continued Elvucitabine Treatment

CompletedNCT00675844

Alexion Pharmaceuticals, Inc.HIV Infections

Start: 2008-05-31End: 2010-03-31Updated: 2023-08-14